Apogee Therapeutics Inc
Research Apogee Therapeutics Inc (APGE) on Bullrun: market cap USD 10.17B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAPGE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 10.17B
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 74.11M
- Free cash flow-USD 55.57M
Valuation Snapshot
latest market cap is USD 10.17B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 255.84M | -USD 232.60M | n/a | -4.22 | USD 131.55M | USD 8.85M | USD 903.88M |
| FY2024 | USD 0 | -USD 182.15M | -USD 172.33M | n/a | -3.3 | USD 141.79M | USD 11.83M | USD 716.79M |
| FY2023 | n/a | -USD 83.99M | -USD 74.93M | n/a | -3.36 | USD 118.32M | USD 2.03M | USD 503.35M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 10.17B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 5.16B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 2.69B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.34B | n/a | n/a | n/a |
About Apogee Therapeutics Inc
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Apogee Therapeutics Inc's market cap?
Apogee Therapeutics Inc's market capitalization is USD 10.17B.
What does Apogee Therapeutics Inc do?
Apogee Therapeutics, Inc., a clinical stage biotechnology company, develops novel biologics for the treatment of atopic dermatitis, asthma, eosinophilic esophagitis, chronic obstructive pulmonary disease, and other inflammatory and immunology indications in the United States. The company develops Zumilokibart (APG777), a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for the treatment of atopic dermatitis, which is in phase 2 clinical trials; and for the treatment of asthma and eosinophilic esophagitis which is in phase 1 clinical trial.